TGTX vs. DCPH, GERN, VERA, MRVI, ARVN, DYN, KROS, AMPH, RCKT, and NAMS
Should you be buying TG Therapeutics stock or one of its competitors? The main competitors of TG Therapeutics include Deciphera Pharmaceuticals (DCPH), Geron (GERN), Vera Therapeutics (VERA), Maravai LifeSciences (MRVI), Arvinas (ARVN), Dyne Therapeutics (DYN), Keros Therapeutics (KROS), Amphastar Pharmaceuticals (AMPH), Rocket Pharmaceuticals (RCKT), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical preparations" industry.
Deciphera Pharmaceuticals (NASDAQ:DCPH) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, community ranking, analyst recommendations, dividends, media sentiment and earnings.
TG Therapeutics has a net margin of 5.42% compared to TG Therapeutics' net margin of -119.33%. Deciphera Pharmaceuticals' return on equity of 12.89% beat TG Therapeutics' return on equity.
TG Therapeutics has higher revenue and earnings than Deciphera Pharmaceuticals. Deciphera Pharmaceuticals is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.
Deciphera Pharmaceuticals has a beta of 0.2, indicating that its stock price is 80% less volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.3, indicating that its stock price is 130% more volatile than the S&P 500.
71.0% of Deciphera Pharmaceuticals shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 4.4% of Deciphera Pharmaceuticals shares are owned by insiders. Comparatively, 9.2% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
TG Therapeutics received 329 more outperform votes than Deciphera Pharmaceuticals when rated by MarketBeat users. Likewise, 76.71% of users gave TG Therapeutics an outperform vote while only 64.91% of users gave Deciphera Pharmaceuticals an outperform vote.
Deciphera Pharmaceuticals currently has a consensus target price of $24.17, suggesting a potential downside of 4.69%. TG Therapeutics has a consensus target price of $29.00, suggesting a potential upside of 82.62%. Given Deciphera Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe TG Therapeutics is more favorable than Deciphera Pharmaceuticals.
In the previous week, Deciphera Pharmaceuticals had 27 more articles in the media than TG Therapeutics. MarketBeat recorded 45 mentions for Deciphera Pharmaceuticals and 18 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.27 beat Deciphera Pharmaceuticals' score of -1.00 indicating that Deciphera Pharmaceuticals is being referred to more favorably in the media.
Summary
TG Therapeutics beats Deciphera Pharmaceuticals on 14 of the 18 factors compared between the two stocks.
Get TG Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TG Therapeutics Competitors List
Related Companies and Tools
